CD274 and neoplasm: Anti-PD-1/PD-L1 treatments are considered to be the cornerstone of 1L therapy for patients with aNSCLC lacking a targetable driver alteration, prescribed as monotherapy for patients with aNSCLC with tumour cell PD-L1 expression ≥ 50%, and typically as combination regimens with platinum-doublet chemotherapies for patients with low or absent PD-L1 expression [36].